Aridis Pharmaceuticals Analysis
| ARDSDelisted Stock | USD 0.27 0.02 8.00% |
Aridis Pharmaceuticals is overvalued with Real Value of 0.23 and Hype Value of 0.27. The main objective of Aridis Pharmaceuticals pink sheet analysis is to determine its intrinsic value, which is an estimate of what Aridis Pharmaceuticals is worth, separate from its market price. There are two main types of Aridis Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Aridis Pharmaceuticals pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Aridis |
Aridis Pink Sheet Analysis Notes
About 32.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.15. Aridis Pharmaceuticals had not issued any dividends in recent years. Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California. Aridis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 34 people.The quote for Aridis Pharmaceuticals is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Aridis Pharmaceuticals please contact Vu Truong at 408 385 1742 or go to https://www.aridispharma.com.Aridis Pharmaceuticals Investment Alerts
| Aridis Pharmaceuticals is not yet fully synchronised with the market data | |
| Aridis Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Aridis Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Aridis Pharmaceuticals currently holds 6.13 M in liabilities. Aridis Pharmaceuticals has a current ratio of 0.4, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aridis Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Aridis Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aridis Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aridis to invest in growth at high rates of return. When we think about Aridis Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (30.37 M) with loss before overhead, payroll, taxes, and interest of (22.61 M). | |
| Aridis Pharmaceuticals currently holds about 6.32 M in cash with (29.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 32.0% of the company shares are held by company insiders | |
| Latest headline from simplywall.st: Virax Biolabs Group First Half 2025 Earnings US0.89 loss per share |
Aridis Pharmaceuticals Upcoming and Recent Events
| 15th of August 2023 Upcoming Quarterly Report | View | |
| 20th of November 2023 Next Financial Report | View | |
| 30th of June 2023 Next Fiscal Quarter End | View | |
| 27th of May 2024 Next Fiscal Year End | View | |
| 31st of March 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Aridis Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.24 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aridis Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Aridis Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Aridis Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aridis Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aridis Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aridis Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hamilton John F over a year ago Exercise or conversion by Hamilton John F of 5000 shares of Aridis Pharmaceuticals subject to Rule 16b-3 |
Aridis Pharmaceuticals Outstanding Bonds
Aridis Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aridis Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aridis bonds can be classified according to their maturity, which is the date when Aridis Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Aridis Pharmaceuticals Predictive Daily Indicators
Aridis Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aridis Pharmaceuticals pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About Aridis Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Aridis Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aridis shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Aridis Pharmaceuticals. By using and applying Aridis Pink Sheet analysis, traders can create a robust methodology for identifying Aridis entry and exit points for their positions.
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California. Aridis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 34 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Aridis Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Volatility Analysis Now
Volatility AnalysisGet historical volatility and risk analysis based on latest market data |
| All Next | Launch Module |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Aridis Pink Sheet
If you are still planning to invest in Aridis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aridis Pharmaceuticals' history and understand the potential risks before investing.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |